schliessen

Filtern

 

Bibliotheken

Cortical Metabolites as Biomarkers in the R6/2 Model of Huntington's Disease

To improve the ability to move from preclinical trials in mouse models of Huntington's disease (HD) to clinical trials in humans, biomarkers are needed that can track similar aspects of disease progression across species. Brain metabolites, detectable by magnetic resonance spectroscopy (MRS), have b... Full description

Journal Title: Journal of Cerebral Blood Flow & Metabolism March 2012, Vol.32(3), pp.502-514
Main Author: Zacharoff, Lori
Other Authors: Tkac, Ivan , Song, Qingfeng , Tang, Chuanning , Bolan, Patrick J , Mangia, Silvia , Henry, Pierre-Gilles , Li, Tongbin , Dubinsky, Janet M
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0271-678X ; E-ISSN: 1559-7016 ; DOI: 10.1038/jcbfm.2011.157
Link: https://journals.sagepub.com/doi/full/10.1038/jcbfm.2011.157
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: sage_s10_1038_jcbfm_2011_157
title: Cortical Metabolites as Biomarkers in the R6/2 Model of Huntington's Disease
format: Article
creator:
  • Zacharoff, Lori
  • Tkac, Ivan
  • Song, Qingfeng
  • Tang, Chuanning
  • Bolan, Patrick J
  • Mangia, Silvia
  • Henry, Pierre-Gilles
  • Li, Tongbin
  • Dubinsky, Janet M
subjects:
  • Biomarker
  • in-Vivo1h Mr Spectroscopy
  • Metabolite Profiles
  • Metabolomics
  • Principal-Least Square Discriminant Analysis
  • Chemistry
  • Anatomy & Physiology
ispartof: Journal of Cerebral Blood Flow & Metabolism, March 2012, Vol.32(3), pp.502-514
description: To improve the ability to move from preclinical trials in mouse models of Huntington's disease (HD) to clinical trials in humans, biomarkers are needed that can track similar aspects of disease progression across species. Brain metabolites, detectable by magnetic resonance spectroscopy (MRS), have been suggested as potential biomarkers in HD. In this study, the R6/2 transgenic mouse model of HD was used to investigate the relative sensitivity of the metabolite profiling and the brain volumetry to anticipate the disease progression. Magnetic resonance imaging (MRI) and 1H MRS data were acquired at 9.4 T from the R6/2 mice and wild-type littermates at 4, 8, 12, and 15 weeks. Brain shrinkage was detectable in striatum, cortex, thalamus, and hypothalamus by 12 weeks. Metabolite changes in cortex paralleled and sometimes preceded those in striatum. The entire set of metabolite changes was compressed into principal components (PCs) using Partial Least Squares-Discriminant Analysis...
language: eng
source:
identifier: ISSN: 0271-678X ; E-ISSN: 1559-7016 ; DOI: 10.1038/jcbfm.2011.157
fulltext: fulltext
issn:
  • 0271-678X
  • 0271678X
  • 1559-7016
  • 15597016
url: Link


@attributes
ID967374417
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10_1038_jcbfm_2011_157
sourceidsage_s
recordidTN_sage_s10_1038_jcbfm_2011_157
sourcesystemPC
dbid
054M
1AAGMC
2AAMGE
3AAMPI
4AARDL
5AATBZ
6AAUAS
7ABAWP
8ABJUO
9ABNCE
10ABNLC
11ABQXT
12ABXGC
13ACDXX
14ACGZU
15ACJTF
16ACTQU
17ADGDL
18AECGH
19AEUIJ
20AGWFA
21AIFIH
22AMCVQ
23BFDSU
24BKSCU
25DC.
26DV7
27J8X
28K.F
29SCNPE
30SFC
31SHG
32SPQ
33SPV
pqid1038135645
display
typearticle
titleCortical Metabolites as Biomarkers in the R6/2 Model of Huntington's Disease
creatorZacharoff, Lori ; Tkac, Ivan ; Song, Qingfeng ; Tang, Chuanning ; Bolan, Patrick J ; Mangia, Silvia ; Henry, Pierre-Gilles ; Li, Tongbin ; Dubinsky, Janet M
ispartofJournal of Cerebral Blood Flow & Metabolism, March 2012, Vol.32(3), pp.502-514
identifier
subjectBiomarker ; in-Vivo1h Mr Spectroscopy ; Metabolite Profiles ; Metabolomics ; Principal-Least Square Discriminant Analysis ; Chemistry ; Anatomy & Physiology
descriptionTo improve the ability to move from preclinical trials in mouse models of Huntington's disease (HD) to clinical trials in humans, biomarkers are needed that can track similar aspects of disease progression across species. Brain metabolites, detectable by magnetic resonance spectroscopy (MRS), have been suggested as potential biomarkers in HD. In this study, the R6/2 transgenic mouse model of HD was used to investigate the relative sensitivity of the metabolite profiling and the brain volumetry to anticipate the disease progression. Magnetic resonance imaging (MRI) and 1H MRS data were acquired at 9.4 T from the R6/2 mice and wild-type littermates at 4, 8, 12, and 15 weeks. Brain shrinkage was detectable in striatum, cortex, thalamus, and hypothalamus by 12 weeks. Metabolite changes in cortex paralleled and sometimes preceded those in striatum. The entire set of metabolite changes was compressed into principal components (PCs) using Partial Least Squares-Discriminant Analysis...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://journals.sagepub.com/doi/full/10.1038/jcbfm.2011.157$$EView_record_in_Sage_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Zacharoff, Lori
1Tkac, Ivan
2Song, Qingfeng
3Tang, Chuanning
4Bolan, Patrick J
5Mangia, Silvia
6Henry, Pierre-Gilles
7Li, Tongbin
8Dubinsky, Janet M
titleCortical Metabolites as Biomarkers in the R6/2 Model of Huntington's Disease
description

To improve the ability to move from preclinical trials in mouse models of Huntington's disease (HD) to clinical trials in humans, biomarkers are needed that can track similar aspects of disease progression across species. Brain metabolites, detectable by magnetic resonance spectroscopy (MRS), have been suggested as potential biomarkers in HD. In this study, the R6/2 transgenic mouse model of HD was used to investigate the relative sensitivity of the metabolite profiling and the brain volumetry to anticipate the disease progression. Magnetic resonance imaging (MRI) and 1H MRS data were acquired at 9.4 T from the R6/2 mice and wild-type littermates at 4, 8, 12, and 15 weeks. Brain shrinkage was detectable in striatum, cortex, thalamus, and hypothalamus by 12 weeks. Metabolite changes in cortex paralleled and sometimes preceded those in striatum. The entire set of metabolite changes was compressed into principal components (PCs) using Partial Least Squares-Discriminant Analysis...

subject
0Biomarker
1in-Vivo1h Mr Spectroscopy
2Metabolite Profiles
3Metabolomics
4Principal-Least Square Discriminant Analysis
5Chemistry
6Anatomy & Physiology
general
0English
1SAGE Publications
210.1038/jcbfm.2011.157
3Sage Journals (Sage Publications)
4SAGE Clinical Medicine (Sage Publications)
5SAGE Health Sciences (Sage Publications)
6SAGE STM (Sage Publications)
7SAGE Neurology (Sage Publications)
8SAGE Cardiology and Cardiovascular Medicine (Sage Publications)
9SAGE Communication and Media Studies (Sage Publications)
10SAGE Journals (Sage Publications)
sourceidsage_s
recordidsage_s10_1038_jcbfm_2011_157
issn
00271-678X
10271678X
21559-7016
315597016
rsrctypearticle
creationdate2012
addtitleJournal of Cerebral Blood Flow & Metabolism
searchscope
0sage_full
1sage32
2sage27
3sage44
4sage219
5sage139
6sage255
7sage29
8sage269
9sage220
10sage183
11sage270
12sage221
13sage17
14sage134
15sage28
16sage273
17sage257
18sage135
19sage272
20sage256
21sage264
22sage136
23sage263
24sage30
25sage282
26sage42
27sage40
28sage31
29sage11
30sage35
31sage34
32sage33
scope
0sage_full
1sage32
2sage27
3sage44
4sage219
5sage139
6sage255
7sage29
8sage269
9sage220
10sage183
11sage270
12sage221
13sage17
14sage134
15sage28
16sage273
17sage257
18sage135
19sage272
20sage256
21sage264
22sage136
23sage263
24sage30
25sage282
26sage42
27sage40
28sage31
29sage11
30sage35
31sage34
32sage33
lsr44$$EView_record_in_Sage_(Access_to_full_text_may_be_restricted)
tmp01
0Sage Journals (Sage Publications)
1SAGE Clinical Medicine (Sage Publications)
2SAGE Health Sciences (Sage Publications)
3SAGE STM (Sage Publications)
4SAGE Neurology (Sage Publications)
5SAGE Cardiology and Cardiovascular Medicine (Sage Publications)
6SAGE Communication and Media Studies (Sage Publications)
7SAGE Journals (Sage Publications)
tmp02
054M
1AAGMC
2AAMGE
3AAMPI
4AARDL
5AATBZ
6AAUAS
7ABAWP
8ABJUO
9ABNCE
10ABNLC
11ABQXT
12ABXGC
13ACDXX
14ACGZU
15ACJTF
16ACTQU
17ADGDL
18AECGH
19AEUIJ
20AGWFA
21AIFIH
22AMCVQ
23BFDSU
24BKSCU
25DC.
26DV7
27J8X
28K.F
29SCNPE
30SFC
31SHG
32SPQ
33SPV
startdate20120301
enddate20120331
lsr40Journal of Cerebral Blood Flow & Metabolism, March 2012, Vol.32 (3), pp.502-514
doi10.1038/jcbfm.2011.157
citationpf 502 pt 514 vol 32 issue 3
lsr30VSR-Enriched:[pqid]
sort
titleCortical Metabolites as Biomarkers in the R6/2 Model of Huntington's Disease
authorZacharoff, Lori ; Tkac, Ivan ; Song, Qingfeng ; Tang, Chuanning ; Bolan, Patrick J ; Mangia, Silvia ; Henry, Pierre-Gilles ; Li, Tongbin ; Dubinsky, Janet M
creationdate20120300
lso0120120300
facets
frbrgroupid8446606891286074485
frbrtype5
newrecords20170607
languageeng
topic
0Biomarker
1in-Vivo1h Mr Spectroscopy
2Metabolite Profiles
3Metabolomics
4Principal-Least Square Discriminant Analysis
5Chemistry
6Anatomy & Physiology
collectionSage Journals (Sage Publications)
prefilterarticles
rsrctypearticles
creatorcontrib
0Zacharoff, Lori
1Tkac, Ivan
2Song, Qingfeng
3Tang, Chuanning
4Bolan, Patrick J
5Mangia, Silvia
6Henry, Pierre-Gilles
7Li, Tongbin
8Dubinsky, Janet M
jtitleJournal of Cerebral Blood Flow & Metabolism
creationdate2012
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Zacharoff
1Tkac
2Song
3Tang
4Bolan
5Mangia
6Henry
7Li
8Dubinsky
aufirst
0Lori
1Ivan
2Qingfeng
3Chuanning
4Patrick J
5Silvia
6Pierre-Gilles
7Tongbin
8Janet M
auinitL
auinit1L
au
0Zacharoff, Lori
1Tkac, Ivan
2Song, Qingfeng
3Tang, Chuanning
4Bolan, Patrick J
5Mangia, Silvia
6Henry, Pierre-Gilles
7Li, Tongbin
8Dubinsky, Janet M
atitleCortical Metabolites as Biomarkers in the R6/2 Model of Huntington's Disease
jtitleJournal of Cerebral Blood Flow & Metabolism
risdate201203
volume32
issue3
spage502
epage514
pages502-514
issn0271-678X
eissn1559-7016
formatjournal
genrearticle
ristypeJOUR
abstract

To improve the ability to move from preclinical trials in mouse models of Huntington's disease (HD) to clinical trials in humans, biomarkers are needed that can track similar aspects of disease progression across species. Brain metabolites, detectable by magnetic resonance spectroscopy (MRS), have been suggested as potential biomarkers in HD. In this study, the R6/2 transgenic mouse model of HD was used to investigate the relative sensitivity of the metabolite profiling and the brain volumetry to anticipate the disease progression. Magnetic resonance imaging (MRI) and 1H MRS data were acquired at 9.4 T from the R6/2 mice and wild-type littermates at 4, 8, 12, and 15 weeks. Brain shrinkage was detectable in striatum, cortex, thalamus, and hypothalamus by 12 weeks. Metabolite changes in cortex paralleled and sometimes preceded those in striatum. The entire set of metabolite changes was compressed into principal components (PCs) using Partial Least Squares-Discriminant Analysis...

copLondon, England
pubSAGE Publications
doi10.1038/jcbfm.2011.157
lad01Journal of Cerebral Blood Flow & Metabolism
date2012-03